Azacitidine: in myelodysplastic syndromes

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
• MDS is characterized by ineffective hematopoiesis and a high risk of transformation to acute myeloid leukemia.
• Current treatment options for MDS have limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

• To evaluate the efficacy and safety of azacitidine in patients with myelodysplastic syndromes (MDS).
• To compare the clinical response and health-related quality of life in MDS patients treated with azacitidine versus supportive care alone.

Main Methods:

• A randomized controlled trial involving 191 patients with MDS.
• Patients received subcutaneous azacitidine (75-100 mg/m2/day for 7 days every 28 days) with supportive care or supportive care alone.
• Health-related quality of life measures, including fatigue and physical functioning, were assessed.

Main Results:

• Azacitidine treatment resulted in a significantly higher response rate (60%) compared to supportive care alone (5%; p<0.001).
• Patients switched to azacitidine after 4 months showed a 47% response rate.
• Clinical response to azacitidine was associated with significant improvements in health-related quality of life (p

Conclusions:

• Azacitidine is an effective treatment for MDS, demonstrating superior response rates and improved quality of life.
• The drug was generally well tolerated, with manageable and transient myelotoxicity.
• Azacitidine offers a promising therapeutic option for patients with MDS, improving outcomes and well-being.